{"id":"lucentis-intravitreal-injection","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Conjunctival hemorrhage"},{"rate":"5-10","effect":"Eye pain"},{"rate":"5-10","effect":"Floaters"},{"rate":"5-10","effect":"Intraocular pressure elevation"},{"rate":"0.05-0.1","effect":"Endophthalmitis"},{"rate":"<1","effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and neutralizes all active forms of VEGF-A, a key driver of pathological neovascularization and vascular leakage in retinal diseases. By blocking VEGF-A signaling, it prevents endothelial cell proliferation and reduces fluid accumulation in the retina, thereby slowing or halting vision loss in conditions characterized by abnormal retinal vasculature.","oneSentence":"Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce vascular permeability in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:36.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT07007065","phase":"PHASE3","title":"Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":561},{"nctId":"NCT06176352","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-03-06","conditions":"Choroidal Neovascularization Secondary to Pathologic Myopia","enrollment":280},{"nctId":"NCT05217680","phase":"PHASE3","title":"Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-05-24","conditions":"Diabetic Macular Edema","enrollment":510},{"nctId":"NCT04853251","phase":"PHASE4","title":"A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-12-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":188},{"nctId":"NCT04108156","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-09-30","conditions":"Diabetic Macular Edema","enrollment":634},{"nctId":"NCT06847542","phase":"PHASE3","title":"A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-11-27","conditions":"Neovascular Age-related Macular Degeneration","enrollment":250},{"nctId":"NCT04503551","phase":"PHASE3","title":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Diabetic Retinopathy","enrollment":174},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT07389577","phase":"PHASE3","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2022-03-01","conditions":"Wet Age-related Macular Degeneration","enrollment":443},{"nctId":"NCT04567303","phase":"PHASE1, PHASE2","title":"Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Macular Degeneration","enrollment":177},{"nctId":"NCT04690556","phase":"PHASE3","title":"Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2020-09-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":600},{"nctId":"NCT05520177","phase":"PHASE3","title":"A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2022-12-27","conditions":"Branch Retinal Vein Occlusion","enrollment":351},{"nctId":"NCT05439629","phase":"PHASE3","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-07-07","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT07249216","phase":"NA","title":"Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting","status":"RECRUITING","sponsor":"Singapore National Eye Centre","startDate":"2025-07-18","conditions":"Age Related Macular Degeneration","enrollment":117},{"nctId":"NCT06952452","phase":"PHASE3","title":"Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2022-11-18","conditions":"Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT05151731","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-31","conditions":"Diabetic Macular Edema","enrollment":394},{"nctId":"NCT05151744","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-17","conditions":"Diabetic Macular Edema","enrollment":187},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT06234514","phase":"PHASE4","title":"Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab","status":"COMPLETED","sponsor":"Dongyang People's Hospital","startDate":"2023-01-01","conditions":"Macular Cystoid Edema","enrollment":111},{"nctId":"NCT02243878","phase":"PHASE3","title":"Stereotactic Radiotherapy for Wet AMD (STAR)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-12","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":411},{"nctId":"NCT04757610","phase":"PHASE3","title":"OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":986},{"nctId":"NCT04667910","phase":"PHASE2","title":"601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2021-01-27","conditions":"Central Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT04667897","phase":"PHASE2","title":"601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2021-01-28","conditions":"Branch Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT06305416","phase":"PHASE3","title":"A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Incepta Pharmaceuticals Ltd","startDate":"2024-03-30","conditions":"Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema","enrollment":70},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT05003245","phase":"PHASE3","title":"Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-01","conditions":"Age Related Macular Degeneration","enrollment":407},{"nctId":"NCT03844074","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2018-10-01","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":61},{"nctId":"NCT03834753","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2019-06-25","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":228},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT00709527","phase":"PHASE1","title":"ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2008-10-16","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":60},{"nctId":"NCT06190093","phase":"PHASE3","title":"A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2024-01-24","conditions":"Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration","enrollment":400},{"nctId":"NCT06841250","phase":"","title":"Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME","status":"ENROLLING_BY_INVITATION","sponsor":"Sohag University","startDate":"2025-01-16","conditions":"Early OCT Biomarker Changes in Response to Anti-VEGF","enrollment":50},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT06771271","phase":"PHASE1","title":"A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-07-22","conditions":"Diabetic Macular Edema, Uveitic Macular Edema","enrollment":85},{"nctId":"NCT05461339","phase":"PHASE3","title":"TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioDlink Biopharm Co., Ltd.","startDate":"2022-06-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT04740671","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-01","conditions":"Age Related Macular Degeneration","enrollment":410},{"nctId":"NCT05861466","phase":"PHASE4","title":"Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-01-01","conditions":"Diabetic Macular Edema","enrollment":102},{"nctId":"NCT02302079","phase":"PHASE2","title":"A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-12","conditions":"Diabetes Mellitus, Diabetic Macular Edema","enrollment":96},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT01940900","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":627},{"nctId":"NCT01944839","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":619},{"nctId":"NCT03709745","phase":"PHASE4","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"St. Erik Eye Hospital","startDate":"2018-10-18","conditions":"Branch Retinal Vein Occlusion with Macular Edema","enrollment":110},{"nctId":"NCT03630315","phase":"PHASE1","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-02-18","conditions":"Neovascular Age-related Macular Degeneration","enrollment":29},{"nctId":"NCT03927690","phase":"PHASE2","title":"Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-24","conditions":"Diabetic Macular Edema","enrollment":91},{"nctId":"NCT00930189","phase":"PHASE2, PHASE3","title":"Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-04","conditions":"Subfoveal Choroidal Neovascularization","enrollment":""},{"nctId":"NCT04884399","phase":"PHASE1","title":"Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2021-06-03","conditions":"Wet Age-related Macular Degeneration","enrollment":24},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT01089517","phase":"PHASE2","title":"A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2010-03","conditions":"Age-Related Macular Degeneration","enrollment":449},{"nctId":"NCT00569140","phase":"PHASE1","title":"A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2007-12","conditions":"Age-related Macular Degeneration","enrollment":18},{"nctId":"NCT06231121","phase":"","title":"Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2023-12-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":13},{"nctId":"NCT05126966","phase":"PHASE3","title":"A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2023-12-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT06205979","phase":"EARLY_PHASE1","title":"Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-12-12","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT06173245","phase":"NA","title":"Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy","status":"COMPLETED","sponsor":"Egyptian Biomedical Research Network","startDate":"2021-02-01","conditions":"Subfoveal Choroidal Thickness, Intravitreal, Ranibizumab","enrollment":50},{"nctId":"NCT03805100","phase":"PHASE3","title":"Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD","status":"COMPLETED","sponsor":"Xbrane Biopharma AB","startDate":"2019-04-19","conditions":"Macular Degeneration","enrollment":582},{"nctId":"NCT04140448","phase":"","title":"Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Renmin Hospital of Wuhan University","startDate":"2023-10-09","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":60},{"nctId":"NCT03784443","phase":"PHASE2, PHASE3","title":"Combined Ranibizumab and Iluvien for Diabetic Macular Oedema","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2019-09-01","conditions":"Diabetic Macular Edema, Diabetes","enrollment":""},{"nctId":"NCT02511067","phase":"PHASE2","title":"Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-10-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT05138029","phase":"PHASE3","title":"Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2021-11-15","conditions":"Diabetic Retinopathy","enrollment":60},{"nctId":"NCT02623426","phase":"PHASE3","title":"Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2017-03-09","conditions":"Uveitis, Macular Edema","enrollment":194},{"nctId":"NCT00606138","phase":"PHASE1, PHASE2","title":"Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":9},{"nctId":"NCT02559180","phase":"PHASE4","title":"Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab","status":"COMPLETED","sponsor":"Rishi Singh","startDate":"2015-10","conditions":"Diabetic Retinopathy, Macular Edema","enrollment":20},{"nctId":"NCT04991350","phase":"PHASE4","title":"Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Cairo University","startDate":"2021-11-26","conditions":"Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy","enrollment":5},{"nctId":"NCT05480293","phase":"PHASE3","title":"This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-02-14","conditions":"Wet Age-related Macular Degeneration","enrollment":446},{"nctId":"NCT02640664","phase":"PHASE3","title":"Rainbow Extension Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-16","conditions":"Retinopathy of Prematurity (ROP)","enrollment":180},{"nctId":"NCT05716932","phase":"","title":"Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm.","status":"COMPLETED","sponsor":"Dar El Oyoun Hospital","startDate":"2022-12-22","conditions":"Retinal Artery Macroaneurysm","enrollment":14},{"nctId":"NCT05701124","phase":"PHASE3","title":"Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-11-20","conditions":"Retina Disease, Retinopathy of Prematurity, Ranibizumab","enrollment":30},{"nctId":"NCT03963596","phase":"NA","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Pathologic Myopia","enrollment":122},{"nctId":"NCT03690947","phase":"PHASE4","title":"Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2018-10-01","conditions":"Diabetic Macular Edema","enrollment":72},{"nctId":"NCT03054766","phase":"NA","title":"Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2017-02-14","conditions":"Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation","enrollment":80},{"nctId":"NCT01469156","phase":"PHASE1, PHASE2","title":"Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Southeast Retina Center, Georgia","startDate":"2011-09","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":20},{"nctId":"NCT01610557","phase":"PHASE2","title":"Ranibizumab and Bevacizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2012-05","conditions":"Diabetic Macular Edema","enrollment":56},{"nctId":"NCT02157077","phase":"PHASE3","title":"Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2013-12","conditions":"Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration","enrollment":90},{"nctId":"NCT03677934","phase":"PHASE3","title":"A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-09-12","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":415},{"nctId":"NCT04985448","phase":"","title":"Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2022-09","conditions":"Retinopathy of Prematurity","enrollment":1000},{"nctId":"NCT02140151","phase":"PHASE1, PHASE2","title":"Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Southern California Desert Retina Consultants, MC","startDate":"2014-09-17","conditions":"Age-related Macular Degeneration","enrollment":108},{"nctId":"NCT05248334","phase":"PHASE1","title":"A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2022-04-10","conditions":"Diabetic Retinopathy, Postoperative Recurrent Vitreous Hemorrhage, Pars Plana Vitrectomy","enrollment":120},{"nctId":"NCT03725501","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD","status":"COMPLETED","sponsor":"AngioLab, Inc.","startDate":"2018-12-07","conditions":"Age-Related Macular Degeneration","enrollment":126},{"nctId":"NCT00644280","phase":"NA","title":"Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-04","conditions":"Glaucoma","enrollment":11},{"nctId":"NCT05414149","phase":"NA","title":"Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2021-09-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":80},{"nctId":"NCT05408416","phase":"NA","title":"Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2021-09-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":102},{"nctId":"NCT05386160","phase":"PHASE4","title":"Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-07-01","conditions":"Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy","enrollment":96},{"nctId":"NCT05297292","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2021-05-07","conditions":"Wet Age-related Macular Degeneration","enrollment":433},{"nctId":"NCT05282420","phase":"PHASE4","title":"Ranibizumab Versus Aflibercept for CRVO in Young Patients.","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2021-02-01","conditions":"Non-Ischemic Central Retinal Vein Occlusion With Macular Edema","enrollment":40},{"nctId":"NCT05271539","phase":"PHASE3","title":"Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-07-01","conditions":"Diabetic Macular Edema","enrollment":42},{"nctId":"NCT05222633","phase":"","title":"Anti-VEGF in Real-world","status":"UNKNOWN","sponsor":"Wenbin Wei","startDate":"2022-01-01","conditions":"Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane","enrollment":1000},{"nctId":"NCT05186155","phase":"","title":"Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-01-01","conditions":"Retinopathy of Prematurity, Neurodevelopmental Abnormality","enrollment":510},{"nctId":"NCT05110209","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":331541},{"nctId":"NCT05146687","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":369600},{"nctId":"NCT02859441","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2017-01-23","conditions":"Von Hippel-Lindau Syndrome","enrollment":3},{"nctId":"NCT01489189","phase":"PHASE3","title":"Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2012-03","conditions":"Proliferative Diabetic Retinopathy","enrollment":305},{"nctId":"NCT05033106","phase":"PHASE3","title":"Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2020-09-01","conditions":"Retinopathy of Prematurity Both Eyes","enrollment":36},{"nctId":"NCT01922154","phase":"PHASE4","title":"Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2009-02","conditions":"Glaucoma, Neovascular","enrollment":15},{"nctId":"NCT03211234","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2017-07-05","conditions":"Age-Related Macular Degeneration","enrollment":76},{"nctId":"NCT03150589","phase":"PHASE3","title":"A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2018-03-14","conditions":"Age-Related Macular Degeneration","enrollment":705},{"nctId":"NCT02510794","phase":"PHASE2","title":"Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-09-28","conditions":"Macular Degeneration","enrollment":225},{"nctId":"NCT02174211","phase":"NA","title":"A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-06","conditions":"Age Related Macular Degeneration","enrollment":59},{"nctId":"NCT03056092","phase":"PHASE4","title":"Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2017-02-28","conditions":"Age Related Macular Degeneration, Diabetic Macular Edema, Macular Edema","enrollment":168},{"nctId":"NCT04857177","phase":"PHASE3","title":"A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-10-19","conditions":"Neovascular(Wet) Age Related Macular Degeneration","enrollment":312},{"nctId":"NCT03203447","phase":"PHASE3","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","status":"TERMINATED","sponsor":"Clearside Biomedical, Inc.","startDate":"2018-03-05","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":325}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1135,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lucentis intravitreal injection","genericName":"Lucentis intravitreal injection","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce vascular permeability in the eye. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}